Changelog
What changed, and when.
Every change to the data, in plain language, by version. Every printed report names the version it used.
Current datav2026.10.02480 records · updated 2026-10-02
v2026.10.022026-10-02
- AddedFirst public release: 480 medications and substances in five groups: psychotropics, general prescriptions, supplements and over-the-counter products, other substances, and peptides and related injectables.
- AddedPeptides and related injectables (including retatrutide, tesamorelin, BPC-157 and semaglutide combinations), 25 supplements and herbal products (including kanna, phenibut and Amanita muscaria products), cannabis, and common recreational and illicit substances.
- AddedOrforglipron (Foundayo) and insulin glargine–lixisenatide (Soliqua).
- EvidenceEvery entry now states whether published human data exist on combining it with psilocybin: human studies, case reports or surveys only, data from another psychedelic only, or none known. Most entries are in the last group.
- EvidenceMAO inhibitor entries rewritten around the available human data; blood pressure is the observed signal and serotonin toxicity remains theoretical.
- EvidenceLSD studies with antidepressants added and marked as data from another psychedelic, not psilocybin.
- EvidenceTrazodone: a published case in which nightly trazodone left no psychedelic effects from a 25 mg psilocybin dose.
- FlagsEvery pharmacologic flag (serotonergic, blood pressure, seizure threshold, gastric emptying and others) is backed by a public source. 5-HT2A-blocking flags were checked against receptor-binding databases.
- SourcesEvery entry carries at least one citation; most link to the current FDA label on DailyMed.
- Half-livesHalf-lives checked against FDA labels, or the official label in the UK, EU or Canada for drugs not sold in the US. Values not confirmed on a label are not shown.
- Half-livesLabel half-lives added for all GLP-1 medications and for lamotrigine, including how other drugs change lamotrigine’s half-life.
- ColoradoColorado rule summaries checked against the official 4 CCR 755-1 text. Each entry shows whether a Colorado provision names the medication or its class.
- OregonOregon added (OAR 333-333-5050 and the Client Information Form), including the 30-day lithium provision.
- New MexicoNew Mexico added as pending. The proposed Medical Psilocybin Program rules name no medication so far.
- SearchSearch covers brand names, common misspellings, salt and dose suffixes, and street names. Plain-language group terms such as “SSRI”, “benzo”, “the pill” and “blood pressure medication” show the medicines in that group.
- FixedDuplicate entries merged, brand fields cleaned, and ibuprofen and naproxen split into separate entries.